We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants who showed improvements in multilineage blood cell counts, even with daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT05832216.

中文翻译：

---

daratumumab 靶向 CD38 治疗再生障碍性贫血的血小板输注难治性

我们发现，10 名再生障碍性贫血患者中有 8 名在 daratumumab 给药后血小板输注难治性消退。值得注意的是，4 名应答者实现了造血恢复，包括 3 名参与者，即使使用 daratumumab 单药治疗，多系血细胞计数也有所改善。该试验在 www.clinicaltrials.gov 注册为 #NCT05832216。